Bullish case
$395 to $415
More likely if revenue growth stays near the high end of guidance, specialty testing and central labs compound steadily, acquisitions integrate cleanly, and investors pay an 18x multiple on higher adjusted EPS.
Labcorp Holdings Inc. research snapshot
LH AI Stock Analysis
LH AI stock analysis currently reads Labcorp as a high-scale diagnostics and central laboratory services business with durable demand, recurring physician and health-system relationships, and rising specialty testing capability. The setup is not a clean bargain because the stock trades near its recent high and already reflects 2026 adjusted EPS growth, so the LH AI stock forecast should be treated as scenario analysis rather than a precise price prediction.
Current price
$283.86
Market cap
$23.28 billion
AI score
68 / 100
Rating
Scaled diagnostics and central lab compounder with steady guidance, acquisition integration risk, and a full but not extreme valuation
Trend status
Constructive technical trend near the upper part of the 52-week range, with fundamentals tied to 2026 guidance delivery
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Labcorp is a long-listed U.S. large-cap with SEC filings, company earnings releases, exchange market data, analyst coverage, technical data, and independent financial databases available for cross-checking.
- bias Check
- The main AI research risk is over-rating stability because diagnostic testing demand is recurring. The countercheck is whether reimbursement pressure, wage inflation, acquisitions, hospital outreach integrations, and central lab demand can still erode margins or make reported growth lower quality.
- ai Confidence
- High for FY2025 revenue, FY2025 net earnings, Q1 2026 guidance, share count, market cap, cash, debt, and current technical status. Medium for normalized growth because acquisitions, payer mix, utilization, reimbursement, and central lab bookings can change the earnings path.
- investment Certainty
- Medium. The business is understandable and cash generative, but investment certainty is lower than data confidence because the current price requires continued 2026 execution and steady healthcare utilization.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Labcorp runs a scaled diagnostics lab network, specialty testing menu, and central laboratory business serving physicians, hospitals, patients, biopharma customers, and health systems. | High |
| Moat | The moat comes from test menu breadth, national logistics, payer contracts, physician relationships, health-system partnerships, data, and scale. It is meaningful but exposed to reimbursement and service quality pressure. | Medium-high |
| Management | Chairman and CEO Adam Schechter has emphasized diagnostics growth, specialty testing, central lab services, health-system partnerships, acquisitions, dividends, and buybacks. | High |
| Financial trend | FY2025 revenue rose 7.2% to $13.9517 billion, net earnings attributable to Labcorp reached $876.5 million, and Q1 2026 revenue grew 5.8%. | High |
| Valuation | At $283.86, verified math shows about 25.1x TTM EPS, 19.3x FCF per share, 2.7x book value, and 1.7x sales on the inputs used here. | Medium-high |
| Technical trend | LH trades near the upper part of its $241.81 to $293.72 52-week range, while Investing.com describes the daily technical read as Strong Buy. | Medium-high |
| Risk level | Risk is moderate. Demand is defensive, but reimbursement, labor, acquisitions, payer mix, cyber and data privacy, central lab demand, and debt can pressure earnings. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and market data are rich. Forecast confidence is lower because margin and multiple assumptions drive much of the upside. | High data confidence |
| Investment certainty | LH looks like a quality execution watchlist name rather than a high-margin-of-safety setup at the current price. | Medium |
LH AI stock forecast
LH AI Stock Forecast Scenarios
The LH AI stock forecast is scenario math, not a guaranteed target. Using the July 8, 2026 research cutoff, a $283.86 stock price, the $17.70 to $18.35 FY2026 adjusted EPS guidance range midpoint, and a three-year model, the tested outcomes span a bearish area near $223, a base area near $334, and a bullish area near $409 before dividends.
Base case
$325 to $340
More likely if Labcorp delivers 5% annual EPS growth from the FY2026 adjusted EPS midpoint and the market values the business near a 16x forward earnings multiple.
Bearish case
$215 to $230
More likely if reimbursement pressure, wage inflation, integration costs, central lab softness, or payer mix pressure keeps EPS growth near 1% and the market applies a lower multiple.
LH AI technical analysis
LH AI Technical Analysis
LH AI technical analysis is constructive as of the July 8, 2026 data cutoff. MarketWatch showed a $283.86 close on July 7, a $241.81 to $293.72 52-week range, and average volume near 649,000 shares, while Investing.com described the daily technical signal as Strong Buy.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $283.86 | MarketWatch and StockAnalysis both showed the July 7, 2026 close near this level. |
| Near support | $283 to $284 | This is the current close area. Losing it would shift attention back to the lower part of the recent day range. |
| Deeper support | $266 to $267 | TipRanks cited a 200-day moving average near $266.63, making it a deeper trend reference. |
| Resistance | $291 to $294 | MarketWatch showed a recent day high near $291.38 and a 52-week high near $293.72. |
| 50-day moving average | About $261.52 | TipRanks cited the 50-day moving average near this level. Price above it supports the current trend read. |
| 200-day moving average | About $266.63 | A close below the 200-day moving average would weaken the trend-following case. |
| Momentum | Strong Buy with neutral RSI | Investing.com cited a daily Strong Buy technical signal and a 14-day RSI near 48.3, which is neutral rather than overbought. |
| Volume monitor | About 649,000 average shares | MarketWatch cited average volume near 649,000 shares. Breakouts above the high should be judged against this reference. |
| Invalidation | Close below $266 | A decisive break below the 200-day moving average would invalidate the cleaner trend-following setup. |
LH AI trading strategy
LH AI Trading Strategy Framework
The LH AI trading strategy below is a planning framework for risk control, not personal investment advice. It combines price confirmation with evidence that Labcorp can deliver FY2026 revenue, adjusted EPS, free cash flow, and integration targets.
Trend-following setup
Wait for LH to hold the $283 to $284 support area and break above the $291 to $294 resistance zone, then check whether volume exceeds the roughly 649,000 share reference and whether Q2 commentary supports guidance.
Treat a failed breakout back below current support as a warning. A close below the 200-day moving average invalidates the trend setup.
Mean-reversion setup
If LH pulls back toward the $266 to $267 area, compare the lower price with FY2026 adjusted EPS guidance, free cash flow guidance, acquisition integration updates, and Diagnostics Laboratories growth.
Do not average down without a defined exit. A guidance cut or margin reset matters more than the apparent discount to the 52-week high.
Fundamental monitor
Track July 30, 2026 earnings, enterprise revenue growth, adjusted EPS of $17.70 to $18.35, free cash flow, payer reimbursement changes, labor costs, central lab demand, acquisitions, debt, and share repurchases.
Keep position size tied to evidence. Defensive healthcare demand does not remove reimbursement, execution, leverage, or multiple risk.
Investment research summary
Four-master Research Compression
Business essence
Labcorp gets paid to run medical tests, specialty diagnostics, health-system laboratory services, and central lab work for drug development customers. The customer pays for accuracy, speed, access, compliance, and workflow reliability.
Moat
The moat is built from national scale, specimen logistics, payer relationships, broad test menus, specialty capabilities, hospital outreach partnerships, data, and operational density. It can narrow if reimbursement falls or service quality slips.
Munger risk inversion
The thesis fails if reimbursement resets faster than productivity gains, wage inflation persists, acquisitions dilute returns, central lab demand weakens, cyber or data privacy events damage trust, or the stock multiple compresses.
Management
Management has used acquisitions, partnerships, dividends, and buybacks while investing in specialty tests and laboratory infrastructure. The key test is whether capital allocation keeps returns above the cost of debt and integration risk.
Industry trend
Labcorp sits in long-term demand for diagnostics, aging demographics, precision medicine, oncology, women health, neurology, autoimmune testing, and biopharma services. The industry is attractive but regulated and cost sensitive.
Valuation and margin of safety
At $283.86, LH is not priced as a distressed asset. Margin of safety depends on Labcorp converting 2026 adjusted EPS guidance into durable free cash flow while avoiding reimbursement or integration surprises.
Source-backed data
LH Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LH price | $283.86 close on July 7, 2026 | MarketWatch quote | July 8, 2026 |
| Market cap | $23.28 billion | StockAnalysis statistics | July 8, 2026 |
| Shares outstanding | 82.00 million | StockAnalysis statistics | July 8, 2026 |
| FY2025 revenue | $13.9517 billion | Labcorp FY2025 results release | July 8, 2026 |
| FY2025 net earnings attributable to Labcorp | $876.5 million | Labcorp FY2025 results release | July 8, 2026 |
| FY2025 free cash flow | $1.2060 billion | Labcorp FY2025 results release | July 8, 2026 |
| Cash and equivalents | $532.3 million at Dec. 31, 2025 | Labcorp FY2025 results release | July 8, 2026 |
| Total debt | $5.58 billion at Dec. 31, 2025 | Labcorp FY2025 results release | July 8, 2026 |
| Q1 2026 revenue and adjusted EPS | $3.54 billion revenue, $4.25 adjusted EPS | Labcorp Q1 2026 results release | July 8, 2026 |
| FY2026 adjusted EPS guidance | $17.70 to $18.35 | Labcorp Q1 2026 results release | July 8, 2026 |
| 52-week range and average volume | $241.81 to $293.72 range, about 649,000 average shares | MarketWatch quote | July 8, 2026 |
| Daily technical signal and RSI | Strong Buy signal, 14-day RSI near 48.3 | Investing.com technical analysis | July 8, 2026 |
Frequently Asked Questions
Read the HUM AI stock analysisCompare the HCA AI stock analysisExplore the AI stock pickerBuild an AI trading strategy
This LH AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if reimbursement, labor costs, acquisition execution, central lab demand, market multiples, or company guidance change.